The collaboration integrates GOLD — CCDC’s protein-ligand docking software for expert drug discovery — with Dassault Systèmes’ BIOVIA therapeutics design software, now delivered on the cloud as part of Dassault Systèmes’ 3DEXPERIENCE platform. This brings together GOLD’s scientific excellence with the flexibility and scalability of the cloud.
“This partnership cements a long-established and productive relationship between Dassault Systèmes and its BIOVIA applications and CCDC,” said Dr Jürgen Harter, CEO of CCDC. “GOLD on the 3DEXPERIENCE platform will empower even more researchers with the best of science to accelerate discovery using their proven processes. We’re excited to help advance the role of cloud-based, high-throughput virtual screening in the development of critical therapeutics.”
CCDC’s GOLD is a highly configurable, protein-ligand docking software for virtual screening that predicts binding modes of active molecules. The solution is highly regarded within the drug discovery community for its accuracy, reliability, and flexibility. Integrating GOLD with BIOVIA therapeutics design software on the 3DEXPERIENCE platform empowers chemists with a complete modelling solution to accelerate drug discovery.
“In silico drug design is moving from discrete, classical modelling applications to more complete and unified solutions,” said Jason Benedict, Vice President of Research and Development, BIOVIA, Dassault Systèmes. “The 3DEXPERIENCE platform brings it all together: the science of classical modelling, the predictive power of AI, and the connection to research labs. By bringing to the platform world-class partners such as CCDC, we are paving the way to the future of drug discovery.”
To learn more or for press inquiries email hello@ccdc.cam.ac.uk.
Image: A preview of GOLD on the 3DEXPERIENCE platform showing the COVID-19 main protease and its defined binding site, ready for virtual screening